Resistance to the anti-malaria drug artemisinin has now been detected in Myanmar and Vietnam, the WHO said, five years after it warned that the drug was no longer effective in treating the disease on the Cambodia-Thailand border.
"The emergence of artemisinin resistance could undo the enormous progress made towards malaria control and elimination --- and potentially pose a serious global health threat," regional director Shin Young-Soo said in a statement.
"Key development partners strongly support our efforts. However, we still face a funding gap of at least USD 450 million over the next three years."
Malaria, which is caused by a parasite infecting mosquitos that feed on humans, kills 660,000 people each year, according to WHO figures.
Artemisinin-based therapies are the first-line treatment for cases of malaria caused by Plasmodium falciparum, the deadliest strain of the disease.
The drug is credited for the remarkable success in reducing the number of malaria deaths globally in recent years.
"If resistance to artemisinin emerges elsewhere, the consequences for global health could be grave," Shin said.
He said the drug-resistant strain was now found in four of the six states that make up Asia's Greater Mekong region, which also includes Laos and China's Yunnan province.
Resistance to the drug may have been caused by the parasite's long exposure to artemisinin therapies, as well as "substandard or counterfeit" drugs in circulation, the WHO said.
Resistance to other formerly effective malaria drugs had also originated along the Cambodia-Thailand border, before spreading west to South Asia, then Africa where most malaria deaths occur, it added.
Malaria also remains a problem in Malaysia, Papua New Guinea, the Philippines, the Solomon Islands, South Korea and Vanuatu.
The warning came as senior health officials from East Asia and the Western Pacific met in Manila this week to coordinate support for international efforts to contain malaria and other diseases.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
